Diplomat Pharmacy (DPLO) Releases FY18 Earnings Guidance

Diplomat Pharmacy (NYSE:DPLO) issued an update on its FY18 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $(0.10)-$0.03 for the period, compared to the Thomson Reuters consensus estimate of $0.83. The company issued revenue guidance of $5.5-5.7 billion, compared to the consensus revenue estimate of $5.64 billion.

Shares of DPLO stock opened at $20.34 on Wednesday. Diplomat Pharmacy has a 52-week low of $14.50 and a 52-week high of $28.74. The firm has a market capitalization of $1.57 billion, a PE ratio of 24.21 and a beta of 0.95. The company has a quick ratio of 0.63, a current ratio of 0.91 and a debt-to-equity ratio of 0.58.

Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings data on Monday, August 6th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.06). Diplomat Pharmacy had a net margin of 0.06% and a return on equity of 7.86%. The business had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.42 billion. During the same quarter in the prior year, the company posted $0.25 EPS. The company’s quarterly revenue was up 25.8% compared to the same quarter last year. As a group, equities research analysts forecast that Diplomat Pharmacy will post 0.83 earnings per share for the current year.

DPLO has been the subject of a number of recent research reports. ValuEngine upgraded shares of Diplomat Pharmacy from a sell rating to a hold rating in a research note on Tuesday, October 23rd. Zacks Investment Research upgraded shares of Diplomat Pharmacy from a sell rating to a hold rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of Hold and an average price target of $26.90.

In related news, Director Philip R. Hagerman sold 57,500 shares of the stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $19.21, for a total transaction of $1,104,575.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Philip R. Hagerman sold 209,367 shares of the stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $19.07, for a total transaction of $3,992,628.69. The disclosure for this sale can be found here. Company insiders own 24.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Diplomat Pharmacy (DPLO) Releases FY18 Earnings Guidance” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/11/07/diplomat-pharmacy-dplo-releases-fy18-earnings-guidance.html.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

See Also: Google Finance Portfolio Workaround

Earnings History and Estimates for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply